Osiris Therapeutics, a stem cell therapeutic company developing treatments for the inflammatory, orthopedic and cardiovascular areas, registered for an initial public offering Friday morning. Deutsche Bank is the sole underwriter listed on the deal. Terms and timing have yet to be disclosed.
